ArticleFrontiers in cardiovascular medicine2026
Percutaneous coronary intervention in patients aged ≤40 years: a 10-year single-centre cohort study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery disease (CAD) in adults aged ≤40 years is increasing, yet long-term outcomes after percutaneous coronary intervention (PCI) in the drug-eluting stent (DES) era remain unclear. We aimed to identify procedural patterns and prognostic factors in this very young cohort. Methods: This single-centre retrospective cohort study included 312 consecutive patients aged ≤40 years who underwent successful PCI for Results: Patients were 82% men (mean age 36.8 ± 4.9 years) with a median SYNTAX score of 16. Procedural success was 98.4% with 93.9% DES implantation and 85.9% radial access. Over 1,620 patient-years (median 5.2 years), MACCE occurred at 27.8 per 1,000 patient-years (5-year cumulative 14.2%). Cardiac mortality was 3.7 per 1,000 patient-years. Diabetes [adjusted hazard ratios (HR) 1.78, 95% confidence interval (CI) 1.06-2.99], SYNTAX score ≥23 (HR 2.01, 1.19-3.40), and dual antiplatelet therapy <12 months (HR 1.62, 1.00-2.64) independently predicted MACCE. Conclusions: Young adults undergoing PCI exhibit complex anatomy but low cardiac mortality. Diabetes, angiographic complexity, and abbreviated antiplatelet therapy are key drive of adverse events, warranting intensive prevention and optimised antiplatelet strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.